Podcast: PET tracers’ role in precision medicine paradigms for neurodegenerative diseases
In March 2026, Swiss biotech AC Immune presented Phase I data including the first in vivo images of TDP-43 pathology…
All articles by Ross Law
Ross Law
Ross Henry Law is a reporter for Medical Device Network. His key interest areas in healthcare include regulation, mental health, neurology, oncology, and Alzheimer's disease. Ross also has extensive prior experience in covering the captive insurance, retail, and technology sectors.
-
-
Dexcom reports 15% YoY revenue uptick in Q1 yet maintains prior FY26 outlook
Dexcom has reported Q1 revenues of around $1.2bn, indicative of a 15% rise year-over-year (YoY), but will maintain its prior…
-
GE HealthCare’s stock plunges 13% as supply chain costs bite
GE HealthCare reported an impacted profit in Q1 2026 alongside a snipping of its full-year financial outlook, prompting the imaging…
-
Parkinson’s disease: neuromodulation and the search for disease modification
For the 10 million patients living with Parkinson’s disease worldwide, the disease’s symptoms become all-consuming, affecting patients’ quality of life…
-
Axoft raises $55m to advance BCI made of Fleuron
With the completion of a $55m fundraise, Axoft is planning to advance the development of its implantable brain-computer interfaces (iBCI).…
-
CareDx sharpens precision medicine focus with $260m Naveris acquisition
CareDx has agreed to acquire Naveris in a deal worth up to $260m, priming the company to inherit a blood‑based…
-
FDA approves Avatar Medical’s 3D image processing software
Avatar Medical’s software platform for processing CT and MR images into three-dimensional (3D) anatomical models has obtained US Food and…
-
Thermo Fisher agrees to sell microbiology business to Astorg in $1bn deal
Thermo Fisher has agreed to sell its microbiology business in a deal above $1bn to private equity firm Astorg, reflecting…
-
iRhythm demonstrates value in 14-day monitoring for arrhythmia recurrence
New data from iRhythm Technologies has demonstrated that extending the cardiac monitoring duration for arrhythmia recurrence to 14 days resulted…
-
Motif Neurotech secures FDA IDE to initiate depression implant study
The US Food and Drug Administration (FDA) has granted Motif Neurotech an investigational device exemption (IDE) to initiate a study…